CELC’s REVTORPYK gains approval; second-line breast cancer launch planned this quarter
REVTORPYK has received approval for second-line metastatic breast cancer. Commercial launch is planned this quarter, and a supplemental NDA for PIK3CA-mutant patients is under review, supported by strong clinical data and broad market strategy.
REVTORPYK has received approval for second-line metastatic breast cancer, with a commercial launch planned this quarter. A supplemental NDA for PIK3CA mutant patients is under review. The company said strong clinical data, flexible regimens and a robust commercial strategy position the drug for significant market impact.